DE60129550D1 - Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten - Google Patents

Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten

Info

Publication number
DE60129550D1
DE60129550D1 DE60129550T DE60129550T DE60129550D1 DE 60129550 D1 DE60129550 D1 DE 60129550D1 DE 60129550 T DE60129550 T DE 60129550T DE 60129550 T DE60129550 T DE 60129550T DE 60129550 D1 DE60129550 D1 DE 60129550D1
Authority
DE
Germany
Prior art keywords
low dose
immunotherapeic
compounds
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129550T
Other languages
English (en)
Other versions
DE60129550T2 (de
Inventor
Halina Offner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health Science University
US Government
US Department of Veterans Affairs VA
Original Assignee
Oregon Health Science University
US Government
US Department of Veterans Affairs VA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health Science University, US Government, US Department of Veterans Affairs VA filed Critical Oregon Health Science University
Publication of DE60129550D1 publication Critical patent/DE60129550D1/de
Application granted granted Critical
Publication of DE60129550T2 publication Critical patent/DE60129550T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60129550T 2000-05-12 2001-05-11 Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten Expired - Lifetime DE60129550T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20398000P 2000-05-12 2000-05-12
US203980P 2000-05-12
PCT/US2001/040710 WO2001085154A2 (en) 2000-05-12 2001-05-11 Method of treating immune pathologies with low dose estrogen

Publications (2)

Publication Number Publication Date
DE60129550D1 true DE60129550D1 (de) 2007-09-06
DE60129550T2 DE60129550T2 (de) 2008-04-10

Family

ID=22756094

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129550T Expired - Lifetime DE60129550T2 (de) 2000-05-12 2001-05-11 Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten

Country Status (7)

Country Link
US (3) US7371385B2 (de)
EP (1) EP1286664B1 (de)
AT (1) ATE367816T1 (de)
AU (2) AU2001259847B9 (de)
CA (1) CA2408935A1 (de)
DE (1) DE60129550T2 (de)
WO (1) WO2001085154A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209208A1 (en) * 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1390040B1 (de) 2001-05-18 2007-01-03 Pantarhei Bioscience B.V. Pharmaceutishe zusammensetzung für die hormonersatztherapie
ES2296943T3 (es) 2001-05-23 2008-05-01 Pantarhei Bioscience B.V. Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal.
EP1390041B1 (de) 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
ATE347365T1 (de) 2001-11-15 2006-12-15 Pantarhei Bioscience Bv Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
EP1358882A1 (de) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Verwendung von Prodrogue von Estriol sulfamate zur Behandlung von autoimmunischen Erkrankungen
EP1358881A1 (de) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Verwendung von biogenen Estrioldiester-Prodrugs zur Behandlung von Autoimmunkrankheiten
US7923440B2 (en) * 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
WO2003103685A1 (en) 2002-06-11 2003-12-18 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
DK1526856T3 (da) 2002-07-12 2008-03-10 Pantarhei Bioscience Bv Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi
ES2298570T3 (es) 2002-10-23 2008-05-16 Pantarhei Bioscience B.V. Composiciones farmaceuticas que comprenden derivados de estetrol para el uso en la terapia del cancer.
EP1585507A2 (de) * 2003-01-06 2005-10-19 Wyeth Verwendung von alpha -östrogenrezeptormodulatoren zur behandlung der multiplen sklerose
WO2005116047A2 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
ATE477497T1 (de) * 2004-12-08 2010-08-15 Cedars Sinai Medical Center Verfahren zur diagnose von morbus crohn
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2007127981A2 (en) * 2006-04-28 2007-11-08 University Of Rochester Analyte-releasing beads and use thereof in quantitative elispot or fluorispot assay
CN101583363B (zh) 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
EP2164498A4 (de) 2007-06-04 2010-09-08 Univ California Schwangerschaftshormonkombination zur behandlung von autoimmunkrankheiten
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110262365A1 (en) * 2008-11-13 2011-10-27 Alek Itsekson Methods of diagnosing hypersensitivity to a female reproductive hormone and treating medical conditions associated with same
US20110229471A1 (en) * 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
CN102439035A (zh) * 2009-03-17 2012-05-02 佛斯卡专利公司 治疗和/或预防动脉粥样硬化的免疫调节方法和系统，以及相关蛋白、肽和组合物
WO2014085679A1 (en) * 2012-11-27 2014-06-05 Deepath Medical Inc. Methods and combinations of signaling markers for assessment of disease states
US10845363B2 (en) * 2012-11-27 2020-11-24 DeePath Medical Diagnostics, Inc. Cell-specific signaling biomarker analysis by high parameter cytometry; sample processing, assay set-up, method, analysis
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US614192A (en) * 1898-11-15 Automatic locking device for chairs
US183299A (en) * 1876-10-17 Improvement in devices for securing fence-wire to posts
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
US6039947A (en) * 1987-06-24 2000-03-21 Autoimmune, Inc. Peptides derived from immunodominant epitopes of myelin basic protein
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) * 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6464978B1 (en) 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
KR0140841B1 (ko) * 1990-10-15 1998-06-01 조앤 월리스 자기항원의 경구 투여에 의한 자기면역 질병의 치료
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
EP0688223A4 (de) * 1993-03-12 1998-05-13 Cellcor Inc -i(IN VITRO) 'ASSAY' ZUM MESSEN DES GRADES DER AKTIVIERUNG VON IMMUNZELLEN
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5939281A (en) * 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
JPH10175854A (ja) * 1996-10-18 1998-06-30 Dokutaazu Kosumeteikusu:Kk 津液改善用皮膚外用剤
AU741037B2 (en) * 1998-02-23 2001-11-22 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
DK1078263T3 (da) 1998-05-11 2009-11-02 Miltenyi Biotec Gmbh Fremgangsmåde til direkte selektion af antigen-specifikke T-celler
DE19821289A1 (de) 1998-05-13 1999-11-18 Volkmar Schoellhorn Verfahren zur Bestimmung der Aktivität von menschlichen und tierischen Zellen, insbesondere Blutzellen, und Mikrotiterplatten
US6958327B1 (en) * 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
DE50014299D1 (de) * 1999-11-02 2007-06-14 Bayer Schering Pharma Ag 18-nor-steroide als selektiv wirksame estrogene
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases

Also Published As

Publication number Publication date
ATE367816T1 (de) 2007-08-15
WO2001085154A2 (en) 2001-11-15
US20080207580A1 (en) 2008-08-28
EP1286664A2 (de) 2003-03-05
US7731973B2 (en) 2010-06-08
CA2408935A1 (en) 2001-11-15
US7579006B2 (en) 2009-08-25
US7371385B2 (en) 2008-05-13
AU2001259847B8 (en) 2006-02-23
EP1286664B1 (de) 2007-07-25
US20080227761A1 (en) 2008-09-18
WO2001085154A8 (en) 2003-10-30
WO2001085154A3 (en) 2002-08-29
DE60129550T2 (de) 2008-04-10
US20030176409A1 (en) 2003-09-18
AU2001259847B2 (en) 2006-02-02
AU5984701A (en) 2001-11-20
AU2001259847B9 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
DE60129550D1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
EA200001044A2 (ru) Соединения для лечения женской сексуальной дисфункции
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
GB0001309D0 (en) Valve arrangement
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
AU9042201A (en) 1-azabicyclo(2.2.2)octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
EP1543158A4 (de) Regulierte aptamer-therapeutika
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
HUP0300339A2 (hu) Fulvesztrant felhasználása rezisztens emlőrák kezelésében
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
MXPA05010871A (es) Metodos para administrar estrogenos y progestinas.
EA200401303A1 (ru) Лекарственные средства, содержащие стероиды и новое антихолинергическое средство
ATE110269T1 (de) Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung.
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
ATE409042T1 (de) Verwendung von sulodexide zur behandlung von diabetischer nephropathie
DE60202954D1 (de) Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition